Probiotics for infants: exciting research, with a sensible reality check

A recently published infant probiotic study has produced results that deserve attention.

In a Phase II clinical trial conducted in western Kenya, researchers tested three specific probiotic and synbiotic formulations in newborn babies. At six months of age, an important marker of chronic systemic inflammation was elevated in 43% of infants who received no supplement—but in only approximately 2% to 3% of those receiving the study formulations.

That is a substantial difference. Gut-health biomarkers and certain growth-related hormones also improved, while no serious adverse events were attributed to the interventions.

Encouraging? Absolutely.

Proof that every baby should immediately be given any probiotic available on the internet? Not so fast. Your favourite pharmacist has seen the marketing department reaching for the glitter again, and we need to have a calm little chat.

This was important early-life gut research, but it was conducted in a particular population, under particular conditions, using named formulations. It cannot be used to claim that probiotics for infants generally prevent childhood illness—or that Noster Paediatric ProBiotics will reproduce the study’s results.

What did the Kenyan infant probiotic trial investigate?

The study was an open-label, randomised, four-arm Phase II trial involving newborn babies in Homa Bay County in western Kenya.

Researchers were particularly interested in a condition known as environmental enteric dysfunction. This is associated with repeated exposure to intestinal pathogens, poor sanitation and adverse living conditions. It can affect the structure and function of the intestine, reduce nutrient absorption and contribute to persistent inflammation.

This is important context. The infants were not simply a convenient collection of healthy babies selected to test a general wellness supplement. They lived in an environment where intestinal infections, undernutrition and environmental enteric dysfunction were significant concerns.

The newborns had a birth weight of at least 2,000 grams and were randomly assigned to one of four groups:

• a Labinic synbiotic group;
• a Lab4b synbiotic group;
• a Lab4b probiotic group; or
• a control group receiving no supplement.

A probiotic contains selected live microorganisms. A synbiotic combines probiotics with a substrate intended to be used by beneficial microorganisms. Think of it as inviting useful bacteria to dinner and remembering to put something suitable on the table for them.

The study products contained live, multi-strain combinations of identified Bifidobacterium species and members of the Lactobacillaceae family. The supplements were given daily for the first ten days and then weekly until the babies reached six months of age.

What happened to the inflammatory marker?

The trial’s primary outcome was chronic systemic inflammation at six months. Researchers assessed this by measuring plasma alpha-1-acid glycoprotein, with a concentration above 1 g/L classified as elevated.

The results were striking:

• Control group: 60 of 138 infants, or 43%, had an elevated inflammatory marker.
• Labinic synbiotic: 4 of 144 infants, or 3%, had an elevated marker.
• Lab4b synbiotic: 3 of 132 infants, or 2%, had an elevated marker.
• Lab4b probiotic: 3 of 141 infants, or 2%, had an elevated marker.

The study also reported improvements in biomarkers associated with intestinal health and growth hormones. Importantly, no serious adverse events were attributed to the probiotic or synbiotic interventions.

Those numbers are impressive. They justify further investigation and may eventually contribute to practical interventions for vulnerable infant populations.

They do not, however, give us permission to remove the name of the tested formulation, replace it with the word “probiotics” and promise the same result to every baby.

Why strain specificity matters in probiotics for infants

One of the most important lessons in probiotic science is also one of the most frequently ignored: probiotic effects are strain-specific and formulation-specific.

A result obtained with one identified combination of microorganisms does not automatically apply to:

• a different strain from the same species;
• a product containing different organisms;
• a different dose or dosing schedule;
• a product stored or manufactured differently;
• children of another age;
• babies living under different health and environmental conditions; or
• every supplement wearing the word “probiotic” on its label.

It is rather like studying one specific medicine and then announcing that every tablet in the pharmacy will do the same job. They may all be small and arrive in boxes, but that is where the useful comparison ends.

For this reason, Noster ProBiotics cannot—and should not—claim the inflammatory-marker reduction reported in this trial. Our paediatric formulation was not the intervention tested.

Good probiotic communication means discussing the actual product, its identified organisms, its quality and its intended role without borrowing clinical results belonging to a different formulation.

Why the study population matters

The babies in this trial came from a high-risk setting where environmental enteric dysfunction and intestinal pathogen exposure were major concerns.

That makes the research especially valuable for communities facing these challenges. It also means we must be cautious when applying the findings elsewhere.

A healthy South African infant living with reliable sanitation, adequate nutrition and routine healthcare may have a very different starting risk from an infant exposed to repeated intestinal pathogens and undernutrition.

The study therefore does not establish that giving the same intervention to healthy South African babies would produce an equally dramatic difference.

That does not make the research less important. It simply tells us which question the trial answered—and which questions remain waiting politely in the queue.

The dramatic difference isn’t what we are looking for. Mothers reading this article are unlikely to be in a situation needing a “dramatic difference”. However, a small to moderate difference is just as important to a mother here, in South Africa.

What does “open-label Phase II trial” mean?

The trial was open-label, meaning that the families and research team knew which intervention each infant received. Open-label studies can provide valuable information, but knowing the assigned treatment may influence care, reporting or other behaviour.

Laboratory assessment of the primary outcome was blinded, which strengthens that particular measurement. Even so, the overall study design must be considered when interpreting the findings.

It was also a Phase II trial. This stage of research can provide an important indication of biological effect and safety, while helping researchers decide whether larger confirmatory trials are justified.

Phase II is promising territory. It is not the scientific equivalent of “case closed, everyone go home”. Larger studies in different populations would help determine how reproducible the findings are and where these interventions may be most useful.

Does this prove that probiotics prevent illness in babies?

No.

The primary result involved a particular blood biomarker of chronic systemic inflammation. Biomarkers can offer valuable information about biological processes, but a change in a biomarker is not automatically the same as proving fewer infections, fewer allergies or better long-term health.

The trial was not evidence that probiotics generally:

• prevent babies from becoming ill;
• stop childhood allergies;
• prevent eczema;
• guarantee healthy growth;
• replace breastfeeding or suitable infant nutrition;
• replace vaccination; or
• remove the need for appropriate medical care.

Those would be much broader claims than the study can support.

Researchers may use these findings to design longer and larger trials that assess clinical outcomes as the children grow. Until then, the responsible wording is that the named interventions were associated with a marked reduction in the trial’s primary inflammatory marker in this particular infant population.

A little less exciting than “probiotics protect every baby from everything”, perhaps—but considerably more honest.

 

What the study teaches us about the early-life microbiome

The first months of life are an important period in the development of the gut microbiome. Feeding, medicines, birth circumstances, family contact, environmental exposure and many other factors help shape the microbial community.

Gut microorganisms interact with the intestinal lining, nutrients and developing immune system. Researchers are investigating whether carefully selected microbial interventions could support infants facing particular environmental or nutritional risks.

This Kenyan trial provides encouraging evidence that targeted probiotic and synbiotic strategies may influence gut-related biology in early life. It also reminds us that the best research does not treat all probiotics as interchangeable.

The interesting question is not merely, “Do probiotics work?”

We need to ask:

• Which precisely identified strains?
• In which formulation?
• At what dose?
• For how long?
• In which group of infants?
• For which carefully defined outcome?

Those details may not fit neatly into a dramatic social-media headline, but they are where the useful science lives.

Should parents give probiotics to babies?

Parents should discuss probiotic supplementation with an appropriate healthcare professional, especially during infancy.

A doctor or pharmacist can consider the baby’s age, feeding, birth history, medical conditions, medicines and the reason a probiotic is being considered. Professional advice is particularly important if a baby:

• was born prematurely;
• did it go down the birth canal (the start of the immune system development)
• has a weakened immune system;
• is seriously unwell or in hospital;
• has a central venous catheter;
• has a significant medical condition;
• is failing to gain weight appropriately; or
• has persistent diarrhoea, vomiting or other concerning symptoms.

Probiotics should not be used to delay medical assessment. Babies can become dehydrated or seriously unwell quickly, so persistent vomiting, diarrhoea, fever, poor feeding, unusual sleepiness, breathing difficulty or fewer wet nappies require prompt professional attention.

That does not rule out the use of probiotics; it means do not delay in seeking medical help because you have started the baby on probiotics.

The honest Noster ProBiotics message

This trial is excellent evidence-led material because it demonstrates both the potential of microbiome research and the importance of specificity.

We can be genuinely excited that carefully selected live microorganisms may eventually help address important early-life gut-health challenges. We can also remain honest about what one Phase II trial does—and does not—prove.

Noster Paediatric ProBiotics did not participate in this study. We therefore do not claim that our product will reproduce its results, reduce the same inflammatory marker or prevent childhood illness.

Our approach is to support sensible conversations about paediatric gut health, appropriate probiotic selection and responsible daily use. No borrowed laboratory coat, no superhero cape and no promises smuggled in through the back door.

Interesting science deserves enthusiasm. Infant health deserves even greater care.

Frequently asked questions

Did this study find that probiotics reduced inflammation?

Three specific probiotic or synbiotic formulations were associated with a much lower proportion of infants having an elevated inflammatory marker at six months. The result applies to the tested formulations, dosing schedule and Kenyan study population—not to probiotics generally.

Were the probiotics safe?

No serious adverse events were attributed to the interventions during the trial. This is reassuring for the products and population studied, but it does not establish that every probiotic is suitable for every infant.

Does Noster Paediatric ProBiotics produce the same result?

This has not been established. Noster Paediatric ProBiotics was not tested in the study, so the reported reduction must not be attributed to the Noster formulation.

Does the study prove that probiotics prevent childhood illness?

No. The primary outcome was a laboratory marker of chronic systemic inflammation. The trial does not prove that probiotics generally prevent infections, allergies, eczema or other childhood illnesses.

What is a synbiotic?

A synbiotic combines live microorganisms with a substrate intended to be used by beneficial microorganisms. Its effects still depend on the particular organisms, ingredients, dose and population studied.

Can I give a probiotic to my baby?

Some probiotic products may be appropriate for certain infants, but it is sensible to discuss the product and reason for use with a doctor or pharmacist. Professional guidance is particularly important for premature, medically vulnerable or seriously unwell babies.

The friendly pharmacist’s final word

The Kenyan trial produced a genuinely impressive result and gives researchers an excellent reason to continue investigating targeted probiotic and synbiotic interventions during early life.

But the headline must travel with its luggage: named formulations, a high-risk population, an open-label Phase II design and a biomarker-based primary outcome.

Celebrate the research, respect its boundaries and never make one probiotic wear another product’s clinical results.

If you would like help deciding whether a paediatric probiotic is appropriate for your child, speak to us. Your favourite pharmacist is happy to help—and equally happy to confiscate any marketing megaphones found near the nursery.

As a new mother or an experienced mother or women in general, you will find this article to be eye-opening The Hygiene Hypothesis and Probiotics

Resources

• Otiti and colleagues: Pro/synbiotics and gut health in Kenyan infants
• Full study in Cell Reports Medicine
• PROSYNK clinical trial record
• NCCIH: Probiotics—usefulness and safety

This article provides general educational information and does not replace individual advice from your child’s doctor, paediatrician or pharmacist.